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Background. Lung transplant (LTx) is a procedure associated with risk of complications
related to airway stenosis that can be treated with bronchoscopic interventions (BIs). The
aim of the study was to assess the frequency and risk factors associated with increased need
of bronchial interventions in the post-transplant period.
Methods. The retrospective study reviewed cases of 165 patients (63 women) who un-
derwent LTx from April 2013 to June 2019. For dichotomous discrete variables (occur-
rence or lack of intervention) multivariate logistic regression analysis was performed to
assess the aforementioned risk factors.
Results. BIs were required among 38.55% of lung recipients (n ¼ 65). The number of
interventions/patient/y decreases between years 1 and 2 (P < .001), 2 and 3 (P ¼ .013), and
3 and 4 (P < .001); after the fourth year post LTx the differences are not statistically
significant. Each 1 mm Hg above 25 mm Hg of mean pulmonary arterial pressure causes
statistically significant elevation in the number of interventions by 0.7% in the first year
after the procedure. The number of BIs per patient among lung recipients who received a
transplant because of idiopathic pulmonary arterial hypertension was statistically signifi-
cantly higher compared with patients with another underlying lung disease.
Conclusions. Airway complications developed in the post-transplant period caused a
significant number of patients to be in need of BI, especially balloon bronchoplasty. The
highest number of interventions occurred within the first year after LTx, and BI
decreases over time. Mean pulmonary arterial pressure measured during qualification
may have the ability to predict whether the patient would require BI after LTx.*Address correspondence to Martyna Gawęda, Medical Univer-
sity of Silesia; Marii Curie-Skłodowskiej 9, 41-800, Zabrze, Poland.
Tel:þ48 32 373 36 00. E-mail: martyna.gaweda@gmail.comLUNG transplant (LTx) is often the only proper treat-ment for patients with end-stage lung diseases. It is
associated with risk of certain complications: airway,
vascular, pleural, and those associated with the surgical
wound. Some of the most common are complications in the
respiratory tract. Although numerous improvements made in
past decades led to a decrease in overall number of airway
complications (ACs) when compared with the early era ofAuthors. Published by Elsevier Inc. This is an open
le under the CC BY-NC-ND license (http://
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ment of lung transplantation. The associated mortality rate
according to literature varies from 2% to 4%, and the inci-
dence of ACs varies from 1.6% to 32% [1e5]. When it comes
to patients with idiopathic pulmonary arterial hypertension,
such a procedure is associated with higher perioperative risk
and the highest mortality rate of 23% in the first 3 post-
operative months (compared with lung recipients with
chronic obstructive pulmonary disease [COPD] or cystic
fibrosis [CF] who have the lowest unadjusted mortality [9%])
[6]. Factors considered to cause an increased risk of such
complications are duration of cold ischemia time, mechanical
ventilation in both the donor and recipient, use of steroids
and immunosuppressive drugs, length of the donor bronchi,
surgical technique, presence of microbial agents in the
recipient and donor bronchus before surgery, and post-
operative infections [7e13]. There is no universally accepted
system for classifying respiratory complications after LTx.
Four qualification systems have been published in recent
years, although they are not commonly used [7e10].
ACs can be managed with bronchoscopic interventions
(BIs), which includes argon plasma coagulation, balloon
dilation, stenting, laser therapy, and cryotherapy [14,15].
The frequency of these interventions correlates with the
frequency of significant complications in the airways after
transplant and can be used as the indicator of ACs [12]. The
aim of the study was to examine the impact of individual
factors on the frequency of interventions.Fig 1. Interventions per patient in time after transplant.MATERIALS AND METHODS
The study design was single-center retrospective cohort research.
We reviewed cases of 165 patients (63 women [38.18%]) who un-
derwent LTx from April 2013 to June 2019 in Silesian Center for
Heart Diseases (Zabrze, Poland). Median age at referral for LTx
was 41 years. Heart-lung transplant and retransplant recipients were
excluded from the study. The number of procedures of double lung
transplant (DLT) was 106 (63.1%). The most common diagnoses
were as follows: COPD (n ¼ 45); CF (n ¼ 43); primary pulmonary
hypertension (n ¼ 21); interstitial lung disease (ILD) (n ¼ 50), and
other (n ¼ 6). Patients were qualified with following ILDs: idio-
pathic pulmonary fibrosis, sarcoidosis, histiocytosis, hypersensitivity
pneumonitis, and lymphangioleiomyomatosis.
The following diseases were included as other: Osler-Weber-
Rendu syndrome, Williams- Campbell syndrome, bronchiectasis,
and pulmonary embolism. The number of patients with at least 3-,
6-, and 12-month survival was as follows: 143 (86.67%), 136
(82.43%), and 118 (71.52%) patients, respectively.
An additional objective was to assess the impact of pulmonary
hypertension (PH) on AC. For that reason we reviewed cases of 66
patients with right heart catheterization data. The study group
consisted of 26 women (39.39%) and 40 men (60.61%). Median age
at referral for LTx was 51.5 years. PH was defined as mean pul-
monary arterial pressure (mPAP)  25 mm Hg at rest, measured
during right heart catheterization.
Airway Complications
Despite the vastness of the term “airway complication,” this article
describes interventions required in case of any airway stenosis (atthe bronchial anastomosis or lower, eg, bronchus intermedius),
granulation, or presence of necrotic tissue. BIs were as follows:
balloon bronchoplasty, stent placement, argon plasma coagulation,
laser therapy, or cryotherapy. None of the studied patients pre-
sented with partial or total anastomotic dehiscence; therefore, such
complication is not described in this study.
Statistical Analysis
All statistical analyses were performed with SPSS 25.0 (IBM,
Armonk, NY, United States) and R 3.5.3 (The R Foundation for
Statistical Computing, Vienna, Austria). The P levels less than .05
were deemed statistically significant. For analyses involving number
of BI tests adequate for Poisson distribution were used since our
data consisted of counts in a given period of time. Specifically,
univariate and multivariate Poisson regression was used as well as
Poisson test. Interaction effect of variables in multivariate Poisson
regression was assessed with partial response plot. For dichotomous
discrete variables (occurrence or lack of intervention) multivariate
logistic regression analysis was performed. For further analysis
associated with the impact of PH on a studied issue univariate
Poisson regression analyses Holm’s correction was applied to pre-
serve overall a level equal to 0.05.RESULTS
BIs were required among 38.55% of lung recipients
(n ¼ 65). The overall number of interventions performed in
our study group, breaks down as follows: 717 balloon di-
lations, 306 argon plasma coagulations, 165 laser therapies,
165 cryotherapies, and 71 stent placements. Taking into
account the underlying disease, the number of BIs were 359
for COPD (7.98 per patient), 235 for CF (5.47 per patient),
255 for primary pulmonary hypertension with pulmonary
veno-occlusive disease (12.14 per patient), 254 for ILDs
(5.08 per patient), and 132 for other (22 per patient).
The correlation between the number of interventions/
patient/y (IPY) and time after LTx is presented on the Fig 1.
The number of IPY decreases with time, and the differences
between the number of IPY in the first and following years
after LTx are statistically significant (P < .001). What is
more, the number of IPY also decreases between years 1
and 2 (P < .001), 2 and 3 (P ¼ .013), and 3 and 4 (P < .001),
and after the fourth year post LTx the differences are not
statistically significant.
Table 1. Multivariate Logistic Regression Analysis With Consideration of Bronchoscopic Interventions
Parameter Parameter Assessment SE c2 P Value OR
95% CI
Lower Upper
Age, y 0.022 0.035 0.404 .525 1.023 0.955 1.095
Sex, female 0.184 0.647 0.081 .776 1.202 0.338 4.276
BMI 0.275 0.132 4.332 .037 0.760 0.587 0.984
Diagnosis
CF 0.471 1.024 0.738 .691
COPD 0.903 1.056 0.212 .645 1.602 0.215 11,930
Other 1.340 0.957 0.732 .392 2.467 0.312 19,530
Diabetes 0.001 0.001 1.962 .161 0.262 0.040 1.707
Time on waiting list > 365 d 0.409 0.193 0.793 .373 1.001 0.999 1.003
CIT 4.496 .034 1.505 1.031 2.195
Abbreviations: BMI, body mass index; CF, cystic fibrosis; CIT, cold ischemia time; COPD, chronic obstructive pulmonary disease; OR, odds ratio; SE, standard error.
Fig 2. Interventions per patient in time after lung transplant
among patients with PH and those without. PH, pulmonary
hypertension.
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ferences between the number of interventions in the first
year after LTx before 2018 and after 2018 when the change
in surgical technique of bronchial anastomosis has been
implemented. The decrease in overall number of BIs after
2018 can be observed, although the result is not statistically
significant (P ¼ .06). In multivariate logistic regression
analysis, the statistical significance in Table 1 relates to
Wald’s statistics determining the need for performing an
intervention. Statistically significant results encompassed
cold ischemia time and body mass index (BMI).
An increase of BMI by each point reduces the chance of
intervention by 31.6% (1316 times). Nagelkerke’s R-square
model was used to confirm that multivariate logistic
regression analysis satisfactorily predicts the probability of
having to perform interventions (P ¼ .246).
If the procedure was performed before 2018, the proba-
bility of performing an intervention increased 3.6 times.
Compared with DLT, single lung transplant (SLT) is asso-
ciated with a 4.2-fold (95% CI, 5.42-3.32; P < .001) reduced
chance of intervention. A statistically significant result re-
lates to the type of operation performed. Patients after DLT
have 2.2759 times more interventions than patients after
SLT. If we take into account the number of anastomoses
(SLT, 1; DLT, 2), we do not observe any differences be-
tween these 2 groups.
Mean pulmonary arterial pressure in aforementioned
group was 33.92 mm Hg. The number of patients with PH
was 38 (57.57%). Regardless of the underlying disease, the
average mPAP in PH group was 45.43 mm Hg, with
consideration of a given diagnosis, successively: IPAH 59.81
mm Hg (n ¼ 16; 100%), COPD 29.56 mm Hg (n ¼ 9; 30%),
CF 27 mm Hg (n ¼ 1; 50%), ILD 35.14 mm Hg (n ¼ 7;
50%), and other 29 mm Hg (in bronchiectasis) (n ¼ 1;
25%).
In our study group BIs were performed in 43.24% of
recipients with PH (n ¼ 16), while in the non-PH group,
44.83% (n ¼ 13) of patients required an intervention.
The number of interventions per patient in the first year
after LTx among PH group was as follows: IPAH 18.5,
COPD 8.17, and ILD 12.66. The number of interventionsper patient among lung recipients who received transplants
because of IPAH was statistically significantly higher in
comparison with patients with another underlying lung dis-
ease (P < .05).
The data from Poisson regression analysis are presented
in Fig 2. In the first year after LTx, patients with PH had
statistically significant higher incidence of BI than recipients
without PH (P < .05). Moreover, in our study group there
were no BIs observed after the first post-transplant year in
patients without PH.
Mean pulmonary arterial pressure obtained during qual-
ification may have the ability to predict whether the patient
would require BI after LTx. Each 1 mm Hg above 25 mm
Hg of mPAP causes statistically significant elevation in the
number of interventions by 0.7% in the first year after the
procedure.
Moreover, the following risk increases 2.3% for every 1
mm Hg above 25 mm Hg of mPAP in the second year after
the procedure. Taking into consideration Holm’s method
and verifying whether these results are statistically signifi-
cant, we obtain confirmation that in the first and second
year after transplant the results remain statistically signifi-
cant, although in every next year they do not cause a sig-
nificant change in terms of incidence of the interventions.
Entire analysis pertaining this issue is demonstrated in Fig 3.
Fig 3. Univariate Poisson regression
analysis (depicted as Forest plot
analysis) presenting the influence of
pulmonary hypertension on broncho-
scopic intervention in time. LTx, lung
transplant. Holm’s method results in
only first and second year remaining
statistically significant. *P < .05.
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Airway stenosis was noted to be the most common AC in
our study. Because of that, 38.55% of recipients required
BI. Available literature provides data that such complica-
tions occur among 1.6% to 32% [1e4]. The study by Herrera
et al reports that in their facility the incidence of AC per-
tains to 23.8% of all anastomoses. Their work also empha-
sizes the role played by fungal infections [16]. Olland et al
reported the incidence of AC at approximately 20%. Their
study suggests that the change of the surgical technique
pertaining special bronchial trimming as well as using
absorbable sutures [3]. Our study reports significant drop of
ACs requiring the BI after the year 2018, since when our
surgeons changed the way they perform bronchial anasto-
moses. Unabsorbable sutures were replaced by absorbable
ones, which are sewn continuously in the membranous part
and single ones are put in the cartilage part of the bronchus.
Discrete narrowing of the bronchial anastomoses were
present in 4.9% of patients at 1 month and in 2.4% at 6
months after LTx, as reported by Weder et al [17]. Their
study also mentions the impact of fungal infection on the
healing process. This study assesses that number of BIs is
the most frequent during the first year. This finding is
consistent with study published by Santacruz et al, which
claims that ACs occur most often between 2 and 9 months
after the surgical period [2]. Our study assessed that the
number of interventions required by patients decreases over
time. Despite that, the study published by Mazzetta et al
assessed that patients who experienced central airway ste-
nosis in the early post-transplant period will present
persistent obstructive ventilatory pattern despite endoscopic
treatment, and they will experience more frequent and
longer hospitalizations [18]. For these reasons, effort must
be undertaken to prevent AC requiring BI.
To our knowledge, the impact of PH (both primary and
secondary) on the risk of developing ACs has not been
frequently evaluated; the only study that has taken intoconsideration the impact of PH was the study by Hyanga
et al, where in multivariate analysis the impact of PH on AC
remained statistically insignificant [19]. A strength of our
study is the relatively high number of patients with IPAH
and patients with secondary hypertension. In the current
study, we have shown not only that PH predisposes to the
greater risk of occurrence of AC but also the effect of higher
mPAP on the increased risk of complications. What is more,
it is statistically significant that patients with IPAH need
more BI than patients with other underlying diseases.CONCLUSIONS
BIs as a treatment of airway stenoses after LTx remain quite
frequent. The most commonly used intervention seems to
be balloon bronchoplasty. The number of BIs decreases
over time. Improvement of surgical technique is associated
with lesser need for BI. Cold ischemia time and BMI impact
whether the patient will require the intervention. Authors
are aware of study’s limitation, and further research is
required on a larger study group.
Pulmonary hypertension evaluated at qualification for
LTx may anticipate later ACs. The higher mPAP is above 25
mm Hg, the greater chances for future AC. Patients with
IPAH would require more BIs per patient, provided they
will need BI. We have to take this potential risk into account
and reduce any other possible risk factors that may
contribute to the development of AC.REFERENCES
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